WP
NTLA icon

Woodline Partners’s Intellia Therapeutics NTLA Stock Holding History

Woodline Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
1,075,349
+874,351
+435% +$12.2M 0.06% 390
2026
Q1 		$2.58M Hold
200,998
– – 0.01% 774
2025
Q4 		$1.81M Hold
200,998
– – 0.01% 780
2025
Q3 		$3.47M Sell
200,998
-1,018,070
-84% -$12.5M 0.02% 640
2025
Q2 		$11.4M Buy
1,219,068
+1,194,962
+4,957% +$9.81M 0.06% 397
2025
Q1 		$171K Buy
+24,106
New +$243K ﹤0.01% 882
2024
Q4 		– Sell
-481,752
Closed -$9.9M – 975
2024
Q3 		$9.9M Buy
+481,752
New +$11.1M 0.08% 295
2023
Q1 		– Sell
-498,262
Closed -$17.4M – 734
2022
Q4 		$17.4M Buy
498,262
+150,991
+43% +$7.18M 0.23% 128
2022
Q3 		$19.4M Buy
347,271
+288,610
+492% +$17.9M 0.27% 104
2022
Q2 		$3.04M Buy
+58,661
New +$2.98M 0.05% 328

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Woodline Partners's NTLA Position: Q2 2026 in Review

Woodline Partners increased its Intellia Therapeutics (NTLA) stake by 435% in Q2 2026, buying an estimated $12.2M and bringing the position to 1,075,349 shares worth $18.2M. The position accounts for 0.06% of the portfolio, ranked #390.

Woodline Partners first reported a position in NTLA in Q2 2022 and has held it in 10 quarters since. The position peaked at $19.4M in Q3 2022. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Woodline Partners held 1,075,349 shares of Intellia Therapeutics worth $18.2M as of Q2 2026.
  • Woodline Partners bought 874,351 Intellia Therapeutics shares in Q2 2026, an estimated $12.2M.
  • Intellia Therapeutics made up 0.06% of Woodline Partners's portfolio in Q2 2026, its #390 holding.
  • Woodline Partners first reported a position in Intellia Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • Woodline Partners's Intellia Therapeutics position peaked at $19.4M in Q3 2022.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.